Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

76.10 

-0.38 -0.5%

as of Jan 15 '21

52 Week Range:

26.49 81.80


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. It has a collaboration with RadNet, Inc. to advance the use of artificial intelligence in breast health. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Sep '10 Sep '11 Sep '12 Sep '13 Sep '14 Sep '15 Sep '16 Jul '17 Sep '18 Sep '19 Sep '20
Equity (BVPS) 10.41
11.20
11.32
11.02
7.31
7.92
7.36
10.41
9.07
8.28
8.76
growth rate 7.6% 1.1% -2.7% -33.7% 8.3% -7.1% 41.4% -12.9% -8.7% 5.8%
Earnings BIT -54.99
227.39
-61.66
-1,190.00
365.10
483.60
571.30
546.30
508.00
585.80
1,157.30
growth rate 100.0% -100.0% 0.0% 100.0% 32.5% 18.1% -4.4% -7.0% 15.3% 97.6%
Avg.PE -64.50
25.58
-67.10
-3.22
441.83
88.91
31.67
15.22
10.28
10.28
32.11
growth rate 100.0% -100.0% 0.0% 100.0% -79.9% -64.4% -51.9% -32.5% 0.0% 212.4%
ROA -1.11
2.70
-0.89
-12.04
0.20
1.64
4.41
9.88
-1.46
-2.98
16.35
growth rate 100.0% -100.0% 0.0% 100.0% 720.0% 168.9% 124.0% -100.0% 0.0% 100.0%
ROE -2.41
5.58
-2.50
-47.85
0.86
6.35
15.67
30.67
-4.27
-8.96
46.27
growth rate 100.0% -100.0% 0.0% 100.0% 638.4% 146.8% 95.7% -100.0% 0.0% 100.0%
ROIC 0.44
5.49
0.60
-12.12
2.43
4.67
8.05
14.50
-0.12
-1.74
21.61
growth rate 1,147.7% -89.1% -100.0% 100.0% 92.2% 72.4% 80.1% -100.0% 0.0% 100.0%
Cur. Ratio 2.49
2.64
2.36
1.49
2.53
1.34
1.47
0.79
1.23
1.68
1.79
growth rate 6.0% -10.6% -36.9% 69.8% -47.0% 9.7% -46.3% 55.7% 36.6% 6.6%
Quick Ratio 1.81
2.02
1.47
1.13
1.83
0.96
1.10
0.58
0.89
1.17
1.40
growth rate 11.6% -27.2% -23.1% 62.0% -47.5% 14.6% -47.3% 53.5% 31.5% 19.7%
Leverage 2.08
2.04
3.54
4.64
4.08
3.69
3.41
2.87
2.98
3.04
2.66
growth rate -1.9% 73.5% 31.1% -12.1% -9.6% -7.6% -15.8% 3.8% 2.0% -12.5%
Balance Sheet Sep '10 Sep '11 Sep '12 Sep '13 Sep '14 Sep '15 Sep '16 Jul '17 Sep '18 Sep '19 Sep '20
Acct.Receivable 283.10
358.32
421.05
409.30
396.00
416.10
447.00
533.50
579.20
648.70
1,028.90
growth rate 26.6% 17.5% -2.8% -3.3% 5.1% 7.4% 19.4% 8.6% 12.0% 58.6%
Acct.Payable 388.79
459.60
392.30
92.10
117.00
156.90
166.60
192.20
186.50
178.80
growth rate 18.2% -14.6% -76.5% 27.0% 34.1% 6.2% 15.4% -3.0% -4.1%
Cur.Assets 1,098.90
1,342.90
1,563.01
1,624.20
1,565.80
1,265.80
1,326.60
1,478.60
1,723.20
1,793.10
2,222.30
growth rate 22.2% 16.4% 3.9% -3.6% -19.2% 4.8% 11.5% 16.5% 4.1% 23.9%
Total Assets 5,625.80
6,008.78
10,477.11
9,000.80
8,414.70
7,642.50
7,317.00
7,979.60
7,230.90
6,442.10
7,195.80
growth rate 6.8% 74.4% -14.1% -6.5% -9.2% -4.3% 9.1% -9.4% -10.9% 11.7%
Cash 515.60
712.87
566.13
829.40
736.10
491.30
548.40
540.60
666.70
601.80
701.00
growth rate 38.3% -20.6% 46.5% -11.3% -33.3% 11.6% -1.4% 23.3% -9.7% 16.5%
Inventory 192.50
230.54
367.19
289.40
330.60
283.10
274.70
331.60
384.10
444.90
395.10
growth rate 19.8% 59.3% -21.2% 14.2% -14.4% -3.0% 20.7% 15.8% 15.8% -11.2%
Cur.Liabilities 441.90
509.45
661.35
1,088.40
619.60
943.40
901.90
1,865.50
1,402.60
1,070.10
1,239.30
growth rate 15.3% 29.8% 64.6% -43.1% 52.3% -4.4% 106.8% -24.8% -23.7% 15.8%
Liabilities 2,927.30
3,071.89
7,516.08
7,059.30
6,351.70
5,563.30
5,174.30
5,194.90
4,802.10
4,326.40
4,488.50
growth rate 4.9% 144.7% -6.1% -10.0% -12.4% -7.0% 0.4% -7.6% -9.9% 3.8%
LT Debt 1,447.10
1,488.58
4,971.18
4,242.10
4,153.20
3,221.00
3,049.40
2,172.10
2,704.60
2,783.60
2,736.90
growth rate 2.9% 234.0% -14.7% -2.1% -22.5% -5.3% -28.8% 24.5% 2.9% -1.7%
Equity 2,698.50
2,936.90
2,961.03
1,941.50
2,063.00
2,079.20
2,142.70
2,784.70
2,428.80
2,115.70
2,705.20
growth rate 8.8% 0.8% -34.4% 6.3% 0.8% 3.1% 30.0% -12.8% -12.9% 27.9%
Common Shares 259.00
264.00
264.00
269.00
278.00
290.00
286.00
286.00
275.00
269.00
265.00
growth rate 1.9% 0.0% 1.9% 3.4% 4.3% -1.4% 0.0% -3.9% -2.2% -1.5%
Cash Flow Statement Sep '10 Sep '11 Sep '12 Sep '13 Sep '14 Sep '15 Sep '16 Jul '17 Sep '18 Sep '19 Sep '20
Capital Expenditures 46.70
55.66
78.70
90.10
80.20
89.40
94.50
107.60
105.60
109.10
156.40
growth rate 19.2% 41.4% 14.5% -11.0% 11.5% 5.7% 13.9% -1.9% 3.3% 43.4%
Cash Dividends 2.70
0.00
0.00
0.00
growth rate -100.0%
Cash From OA 456.70
456.02
370.20
493.80
508.40
796.80
798.20
8.30
732.90
649.50
896.60
growth rate -0.2% -18.8% 33.4% 3.0% 56.7% 0.2% -99.0% 8,730.1% -11.4% 38.0%
FCF per Share 1.56
1.48
1.27
1.49
1.39
2.10
2.40
-0.16
2.01
1.92
2.15
growth rate -5.1% -14.2% 17.3% -6.7% 51.1% 14.3% -100.0% 100.0% -4.5% 12.0%
Sale Purchase of Stock 15.01
28.60
75.10
81.40
70.00
38.50
49.00
growth rate 90.6% 162.6% 8.4% -14.0% -45.0% 27.3%
FCF 404.00
392.00
287.00
404.00
428.00
697.00
689.00
-99.00
627.00
535.00
740.00
growth rate -3.0% -26.8% 40.8% 5.9% 62.9% -1.2% -100.0% 100.0% -14.7% 38.3%
Income Statement Sep '10 Sep '11 Sep '12 Sep '13 Sep '14 Sep '15 Sep '16 Jul '17 Sep '18 Sep '19 Sep '20
Sales 1,679.60
1,789.35
2,002.60
2,492.30
2,530.70
2,705.00
2,832.70
3,058.80
3,217.90
3,367.30
3,776.40
growth rate 6.5% 11.9% 24.5% 1.5% 6.9% 4.7% 8.0% 5.2% 4.6% 12.2%
Op.Income 69.90
127.26
-115.90
-1,182.00
365.10
483.60
571.30
546.30
508.00
585.80
1,157.30
growth rate 82.1% -100.0% 0.0% 100.0% 32.5% 18.1% -4.4% -7.0% 15.3% 97.6%
IBT -55.00
227.39
-61.70
-1,192.90
48.10
177.20
415.30
1,230.50
-418.60
-257.70
1,001.90
growth rate 100.0% -100.0% 0.0% 100.0% 268.4% 134.4% 196.3% -100.0% 0.0% 100.0%
Net Income -62.80
127.26
-115.90
-1,182.00
17.30
131.60
330.80
755.50
-111.30
-203.60
1,115.20
growth rate 100.0% -100.0% 0.0% 100.0% 660.7% 151.4% 128.4% -100.0% 0.0% 100.0%
EPS -0.24
0.59
-0.28
-4.36
0.06
0.45
1.16
2.64
-0.40
-0.76
4.21
growth rate 100.0% -100.0% 0.0% 100.0% 650.0% 157.8% 127.6% -100.0% 0.0% 100.0%
Gross Profit 736.60
923.18
994.40
1,161.40
1,587.00
1,732.40
1,856.70
1,957.40
2,016.10
2,075.20
2,513.30
growth rate 25.3% 7.7% 16.8% 36.7% 9.2% 7.2% 5.4% 3.0% 2.9% 21.1%
R&D 104.30
116.70
131.00
197.60
203.20
214.90
232.10
232.80
218.70
232.20
222.50
growth rate 11.9% 12.3% 50.8% 2.8% 5.8% 8.0% 0.3% -6.1% 6.2% -4.2%

Quarterly Statements

Item Name Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Earnings BIT 153.10
155.90
159.30
192.00
650.10
growth rate 1.8% 2.2% 20.5% 238.6%
Balance Sheet Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Acct.Receivable 648.70
581.80
597.20
728.00
1,028.90
growth rate -10.3% 2.7% 21.9% 41.3%
Acct.Payable 186.50
123.70
134.40
127.30
178.80
growth rate -33.7% 8.7% -5.3% 40.5%
Cur.Assets 1,793.10
1,637.60
1,936.60
1,982.80
2,222.30
growth rate -8.7% 18.3% 2.4% 12.1%
Total Assets 6,442.10
6,311.90
6,821.80
6,803.10
7,195.80
growth rate -2.0% 8.1% -0.3% 5.8%
Cash 601.80
370.80
799.80
744.20
701.00
growth rate -38.4% 115.7% -7.0% -5.8%
Inventory 444.90
380.80
401.30
413.60
395.10
growth rate -14.4% 5.4% 3.1% -4.5%
Cur.Liabilities 1,070.10
1,043.30
1,480.90
1,345.70
1,239.30
growth rate -2.5% 41.9% -9.1% -7.9%
Liabilities 4,326.40
4,054.20
4,730.60
4,544.50
4,488.50
growth rate -6.3% 16.7% -3.9% -1.2%
LT Debt 2,783.60
2,769.40
2,769.80
2,754.90
2,736.90
growth rate -0.5% 0.0% -0.5% -0.7%
Equity 2,115.70
2,250.80
2,086.10
2,255.10
2,705.20
growth rate 6.4% -7.3% 8.1% 20.0%
Common Shares 2.90
2.90
2.90
2.90
2.90
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Capital Expenditures 31.40
31.50
31.60
35.00
58.30
growth rate 0.3% 0.3% 10.8% 66.6%
Cash Dividends
growth rate
Cash From OA 247.70
113.90
117.70
223.00
442.00
growth rate -54.0% 3.3% 89.5% 98.2%
Sale Purchase of Stock
growth rate
FCF 216.30
82.40
86.10
188.00
383.70
growth rate -61.9% 4.5% 118.4% 104.1%
Income Statement Sep '19 Dec '19 Mar '20 Jun '20 Sep '20
Sales 865.90
850.50
756.10
822.90
1,346.90
growth rate -1.8% -11.1% 8.8% 63.7%
Op.Income 153.10
155.90
159.30
192.00
650.10
growth rate 1.8% 2.2% 20.5% 238.6%
IBT -122.70
97.40
118.90
168.40
617.10
growth rate 100.0% 22.1% 41.6% 266.5%
Net Income -123.50
386.10
96.30
137.90
494.90
growth rate 100.0% -75.1% 43.2% 258.9%
EPS
growth rate
Gross Profit 533.90
523.20
458.70
529.00
1,002.40
growth rate -2.0% -12.3% 15.3% 89.5%
R&D 60.40
61.20
49.30
55.10
57.00
growth rate 1.3% -19.4% 11.8% 3.5%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

C (62.38)

YOY Growth Grade:

E (30.29)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 19.12 18.08 17.02
EPS / Growth 9.2% 4.21 17.4%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 5.1%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 5.1% 10.6% 10.6%
Future PE 10.26 19.09 19.09
Future EPS 6.94 11.49 11.49
Value Price
MOS %
17.61
-76.9%
54.20
-28.8%
54.20
-28.8%
MOS Price 8.80 27.10 27.10
IRT 12.63 9.99 9.99

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.